This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Urologists And Henry Schein Team Up To Urge Families To Put A Prostate Cancer Check-Up On The Back To School List For Dad

MELVILLE, N.Y., Sept. 10, 2012 /PRNewswire/ -- The Large Urology Group Practice Association, representing more than 1,800 urologists nationwide, and Henry Schein Cares, the global corporate social responsibility program of Henry Schein, Inc., are partnering together to raise awareness among families across the country of the importance of putting prostate cancer check-ups on the calendar for the men in their lives. September –  for many families, back-to-school time for the kids – is also Prostate Cancer Awareness Month. To create more public awareness about the importance of early detection of prostate cancer to save men's lives, LUGPA and Henry Schein have launched an educational initiative to put a prostate cancer check-up for Dad on the family's back to school list.

"Prostate cancer can affect any of the men in our lives – our fathers, grandfathers, husbands, brothers, uncles, sons, friends and neighbors – but with early detection this disease is almost always curable," said Dr. Deepak A. Kapoor, president of the Large Urology Group Practice Association and president of Advanced Urology Centers of New York. "As children return to school, this is a great time to remind men to have a discussion with their doctor to determine if they need a prostate check-up. Together we can help ensure that generations of men are there for not only their children's back-to-school, but for their grandkids as well."

According to Dr. Kapoor, one out of six American men will have prostate cancer in their lifetime; the incidence is even higher for African-American men and those with a family history of prostate cancer. Prostate cancer is the most common non-skin malignancy diagnosed in men; with early detection efforts, the death rate from prostate cancer has decreased by over 40% in the United States.

The largest study ever performed on screening for prostate cancer, the European Randomized Study for the Screening of Prostate Cancer (ERSPC), recently released its updated findings (N Engl J Med 2012; 366:981-990) demonstrating that for all patients there was a 21% survival advantage, and more importantly, for those with the longest follow-up (over 10 years), the advantage of screening increased to 38%. "Unfortunately, there are no symptoms during the early stages of prostate cancer, when the disease is most treatable," added Dr. Kapoor. "Despite improvement in patient education and awareness, many men still fall through the cracks; prostate cancer remains the second leading cause of cancer death in American men. The tragedy is that when the disease is caught early, the 10-year survival is almost 99% ... we all need to come together to ensure that our message is heard: early detection saves lives."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs